CL2016000438A1 - Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica - Google Patents

Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica

Info

Publication number
CL2016000438A1
CL2016000438A1 CL2016000438A CL2016000438A CL2016000438A1 CL 2016000438 A1 CL2016000438 A1 CL 2016000438A1 CL 2016000438 A CL2016000438 A CL 2016000438A CL 2016000438 A CL2016000438 A CL 2016000438A CL 2016000438 A1 CL2016000438 A1 CL 2016000438A1
Authority
CL
Chile
Prior art keywords
treatment
csf
cancer
receptor
stimulating factor
Prior art date
Application number
CL2016000438A
Other languages
English (en)
Inventor
Graham Craggs
Karine Jeannine Madeleine Hervé
Diane Marshall
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49397073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000438(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2016000438A1 publication Critical patent/CL2016000438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

ANTICUERPO ANTI-CSF-1R (RECEPTOR DEL FACTOR ESTIMULANTE DE COLONIAS 1); SECUENCIAS DE NUCLEÓTIDOS QUE LO CODIFICAN; VECTOR; CÉLULA HUÉSPED; COMPOSICIÓN FARMACÉUTICA QUE LO COMPRENDE; USO PARA EL TRATAMIENTO DE LA ENFERMEDAD FIBRÓTICA O CÁNCER.
CL2016000438A 2013-08-30 2016-02-25 Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica CL2016000438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1315487.7A GB201315487D0 (en) 2013-08-30 2013-08-30 Antibodies

Publications (1)

Publication Number Publication Date
CL2016000438A1 true CL2016000438A1 (es) 2016-11-11

Family

ID=49397073

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000438A CL2016000438A1 (es) 2013-08-30 2016-02-25 Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica

Country Status (39)

Country Link
US (2) US9908939B2 (es)
EP (3) EP3549599B1 (es)
JP (3) JP6632075B2 (es)
KR (1) KR102303130B1 (es)
CN (2) CN105658236B (es)
AR (2) AR097464A1 (es)
AU (1) AU2014314304B2 (es)
BR (1) BR112016004324B1 (es)
CA (1) CA2922240C (es)
CL (1) CL2016000438A1 (es)
CY (1) CY1121964T1 (es)
DK (2) DK3549599T5 (es)
EA (1) EA036255B1 (es)
ES (2) ES2965207T3 (es)
FI (1) FI3549599T3 (es)
GB (1) GB201315487D0 (es)
HR (2) HRP20231264T1 (es)
HU (2) HUE064437T2 (es)
IL (1) IL244043B (es)
LT (2) LT3038643T (es)
MA (2) MA38930A1 (es)
MX (1) MX372950B (es)
MY (1) MY172484A (es)
NZ (1) NZ717399A (es)
PE (2) PE20201067A1 (es)
PH (1) PH12016500275B1 (es)
PL (2) PL3038643T3 (es)
PT (2) PT3038643T (es)
RS (2) RS59019B1 (es)
SG (1) SG11201601151PA (es)
SI (2) SI3038643T1 (es)
SM (2) SMT201900471T1 (es)
TN (1) TN2016000067A1 (es)
TR (1) TR201909478T4 (es)
TW (1) TWI531582B (es)
UA (1) UA118354C2 (es)
UY (1) UY35718A (es)
WO (1) WO2015028455A1 (es)
ZA (1) ZA201601437B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
JP6851322B2 (ja) * 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル 神経疾患を治療する方法
HK1249016A1 (zh) * 2015-06-02 2018-10-26 豪夫迈‧罗氏有限公司 使用抗il-34抗体治疗神经疾病的组合物和方法
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
US12168054B2 (en) 2017-05-19 2024-12-17 Syndax Pharmaceuticals, Inc. Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
GB201803226D0 (en) 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
CN108948198B (zh) * 2018-07-18 2020-09-01 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及其应用
EP3894014A4 (en) * 2018-12-13 2022-04-20 Development Center for Biotechnology ANTI-HUMAN CSF-1R ANTIBODIES AND USES THEREOF
CN113939539B (zh) * 2019-05-15 2024-06-04 博奥信生物技术（南京）有限公司 结合csf-1r的抗体及其用途
PH12022551401A1 (en) * 2019-12-09 2023-08-23 Syndax Pharmaceuticals Inc Antibodies for the treatment of chronic graft versus host disease
CN114835811B (zh) * 2019-12-24 2024-03-26 宝船生物医药科技(上海)有限公司 抗csf1r分子及其用途
CN121219009A (zh) 2023-05-17 2025-12-26 信达克思制药公司 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病相关的闭塞性细支气管炎综合征的方法
AU2024300057A1 (en) 2023-07-23 2026-01-08 Incyte Corporation Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody
TW202544045A (zh) 2024-04-22 2025-11-16 美商英塞特公司 抗群落刺激因子１受體抗體與ｊａｋ抑制劑之組合療法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
JP5718640B2 (ja) * 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトｃ−ｆｍｓ抗原結合性タンパク質
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
RU2547586C2 (ru) 2008-03-14 2015-04-10 Трансжене С.А. Антитело против csf-1r
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
DK2510010T3 (en) * 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) * 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
EP3943154A1 (en) * 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
MX356337B (es) * 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
GB201315486D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies

Also Published As

Publication number Publication date
JP2016529266A (ja) 2016-09-23
UA118354C2 (uk) 2019-01-10
TN2016000067A1 (en) 2017-07-05
EP3549599B1 (en) 2023-09-06
MA44922A1 (fr) 2019-08-30
RS64784B1 (sr) 2023-11-30
FI3549599T3 (fi) 2023-10-31
WO2015028455A1 (en) 2015-03-05
SI3038643T1 (sl) 2019-08-30
AR097464A1 (es) 2016-03-16
CN105658236A (zh) 2016-06-08
TW201512221A (zh) 2015-04-01
EA201690503A1 (ru) 2016-06-30
EP4282881A2 (en) 2023-11-29
BR112016004324A2 (pt) 2017-10-24
JP7195237B2 (ja) 2022-12-23
PH12016500275A1 (en) 2016-05-02
GB201315487D0 (en) 2013-10-16
CA2922240A1 (en) 2015-03-05
JP2020005652A (ja) 2020-01-16
IL244043A0 (en) 2016-04-21
PH12016500275B1 (en) 2019-11-29
EP3038643B1 (en) 2019-05-01
EP4282881A3 (en) 2024-02-21
ES2965207T3 (es) 2024-04-11
CN112321711B (zh) 2024-11-08
CN112321711A (zh) 2021-02-05
HRP20231264T1 (hr) 2024-02-02
NZ717399A (en) 2021-12-24
RS59019B1 (sr) 2019-08-30
LT3038643T (lt) 2019-07-25
US10421814B2 (en) 2019-09-24
EP3549599A1 (en) 2019-10-09
UY35718A (es) 2015-03-27
LT3549599T (lt) 2023-11-10
TWI531582B (zh) 2016-05-01
US20180162947A1 (en) 2018-06-14
JP2022002523A (ja) 2022-01-11
AU2014314304A1 (en) 2016-03-17
PE20201067A1 (es) 2020-10-19
AR134186A2 (es) 2025-12-10
KR102303130B1 (ko) 2021-09-16
HK1220142A1 (en) 2017-04-28
KR20160044018A (ko) 2016-04-22
DK3038643T3 (da) 2019-06-24
US9908939B2 (en) 2018-03-06
MY172484A (en) 2019-11-26
MA44922B1 (fr) 2020-06-30
ES2733735T3 (es) 2019-12-02
CY1121964T1 (el) 2020-10-14
MX372950B (es) 2020-04-03
HRP20191051T1 (hr) 2019-09-06
MA38930A1 (fr) 2017-12-29
TR201909478T4 (tr) 2019-07-22
US20160200821A1 (en) 2016-07-14
EA036255B1 (ru) 2020-10-20
JP6632075B2 (ja) 2020-01-15
PT3549599T (pt) 2023-11-21
HUE064437T2 (hu) 2024-03-28
MX2016002166A (es) 2016-06-23
PE20160528A1 (es) 2016-05-21
CA2922240C (en) 2023-09-05
SMT202300409T1 (it) 2024-01-10
SI3549599T1 (sl) 2023-12-29
DK3549599T5 (da) 2024-09-02
IL244043B (en) 2021-01-31
EP3038643A1 (en) 2016-07-06
BR112016004324B1 (pt) 2024-01-16
AU2014314304B2 (en) 2019-12-05
PT3038643T (pt) 2019-07-25
ZA201601437B (en) 2018-08-29
HUE045672T2 (hu) 2020-01-28
PL3038643T3 (pl) 2019-11-29
DK3549599T3 (en) 2023-10-30
PL3549599T3 (pl) 2024-03-04
SMT201900471T1 (it) 2019-09-09
CN105658236B (zh) 2021-03-19
SG11201601151PA (en) 2016-03-30

Similar Documents

Publication Publication Date Title
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
BR112016030424A2 (pt) construções de anticorpo multiespecíficas
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
EA201891983A8 (ru) Комбинированная терапия антителами к cd73
CL2017002244A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
CL2018003153A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer.
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
PE20191403A1 (es) Anticuerpos anti-ox40 y sus usos
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
MX383868B (es) Anticuerpos contra cd73 y sus usos.
UY35399A (es) Conjugados de fármacos con anticuerpos
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
MA50584B1 (fr) Molécules bispécifiques de liaison à l'antigène activant des lymphocytes t
CY1120459T1 (el) Αντισωματα των χημειοκινων παν-elr+ cxc